J
Jussi Taipale
Researcher at University of Helsinki
Publications - 171
Citations - 31981
Jussi Taipale is an academic researcher from University of Helsinki. The author has contributed to research in topics: Gene & Transcription factor. The author has an hindex of 64, co-authored 164 publications receiving 27737 citations. Previous affiliations of Jussi Taipale include University of Washington & Ludwig Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
The Human Transcription Factors.
Samuel A. Lambert,Arttu Jolma,Laura F. Campitelli,Pratyush Kumar Das,Yimeng Yin,Mihai Albu,Xiaoting Chen,Jussi Taipale,Jussi Taipale,Jussi Taipale,Timothy P. Hughes,Matthew T. Weirauch,Matthew T. Weirauch +12 more
TL;DR: This review considers how TFs are identified and functionally characterized, principally through the lens of a catalog of over 1,600 likely human TFs and binding motifs for two-thirds of them, highlighting the importance of continued effort to understand TF-mediated gene regulation.
Journal ArticleDOI
Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened.
TL;DR: It is shown that cyclopamine can reverse the retention of partially misfolded Smo in the endoplasmic reticulum through binding-mediated effects on protein conformation, which suggests a role for small molecules in the physiological regulation of Smo.
Journal ArticleDOI
The Hedgehog and Wnt signalling pathways in cancer
Jussi Taipale,Philip A. Beachy +1 more
TL;DR: Evidence suggesting that tumorigenesis associated with pathway activation may result from mis-specification of cells towards stem-cell or stem cell-like fates is reviewed.
Journal ArticleDOI
Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine
Jussi Taipale,James K. Chen,Michael K. Cooper,Baolin Wang,Randall K. Mann,Ljiljana Milenkovic,Matthew P. Scott,Philip A. Beachy +7 more
TL;DR: It is shown that the plant-derived teratogen cyclopamine, which inhibits the Hh response, is a potential ‘mechanism-based’ therapeutic agent for treatment of these tumours.
Journal ArticleDOI
Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.
Marika J. Karkkainen,Paula Haiko,Kirsi Sainio,Juha Partanen,Jussi Taipale,Tatiana V. Petrova,Michael Jeltsch,David A. Jackson,Marja Talikka,Heikki Rauvala,Christer Betsholtz,Kari Alitalo +11 more
TL;DR: The results indicate that VEGF-C is the paracrine factor essential for lymphangiogenesis, and show that both Vegfc alleles are required for normal lymphatic development.